Tysabri and Progressive Multifocal Leukoencephalopathy: Legal Options for Washington Patients

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Risk Awareness

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical risks and therapeutic benefits. This legacy context established a baseline for how individuals evaluate treatment options, particularly for chronic conditions requiring long-term immunosuppression. Within this framework, patients and providers have navigated complex benefit-risk profiles, relying on transparent communication to make informed decisions. As this informational heritage evolved, a specific area of concern emerged regarding the occupational and environmental dimensions of pharmaceutical exposure. The transition from broad health literacy to focused risk assessment becomes necessary when considering the implications of biologic therapies such as Tysabri. While the clinical setting appropriately emphasizes patient outcomes, the occupational exposure concern arises for professionals who handle, administer, or come into contact with these agents in their work environments. This pivot acknowledges that the same scientific rigor applied to patient education must extend to those whose daily responsibilities involve potential contact with immunosuppressive medications. The shift in perspective moves from general health awareness to a targeted examination of how workplace practices intersect with pharmaceutical risk management, particularly regarding the rare but serious condition of progressive multifocal leukoencephalopathy. This transition sets the stage for a more detailed exploration of liability and safety protocols in occupational contexts.

Find Out If You Qualify for Compensation →

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. This section summarizes the clinical presentation, pharmacological link, and risk considerations, including settlement-related factors for affected patients. Progressive multifocal leukoencephalopathy is a demyelinating disease of the central nervous system that results from reactivation of the JC virus in immunocompromised individuals. Clinical presentation typically includes subacute onset of neurological deficits such as weakness, cognitive decline, visual disturbances, and ataxia. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction. The condition usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Tysabri is a monoclonal antibody that binds to alpha-4 integrins, preventing lymphocyte migration into the brain. This mechanism reduces inflammatory activity in multiple sclerosis but also impairs immune surveillance against JC virus. The FDA-approved labeling includes a boxed warning stating that TYSABRI increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Risk Factors and Mechanisms of PML in Tysabri Patients

Three risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The mechanistic pathway linking Tysabri to PML involves reduced immune surveillance in the central nervous system. By blocking lymphocyte trafficking, Tysabri diminishes the ability of the immune system to control JC virus replication, allowing the virus to infect oligodendrocytes and cause demyelination. This effect is dose- and duration-dependent, with longer exposure increasing cumulative risk. In clinical trials, PML occurred in three patients who received TYSABRI: two among 1869 multiple sclerosis patients treated for a median of 120 weeks (both also received interferon beta-1a), and one after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Risk anchors for patients and healthcare providers include the adequacy of warnings and the timeline between exposure and harm. The boxed warning explicitly states that TYSABRI increases PML risk and that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML, with dosing withheld immediately at first suspicion (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, PML can still occur, and the latency period varies from months to years. The TOUCH Prescribing Program is a restricted distribution system designed to ensure patients are informed of risks and monitored, but it does not eliminate the possibility of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Legal Considerations and Settlement Factors for PML After Tysabri

For patients who develop PML after Tysabri exposure, settlement-related considerations may arise. The documented harm—severe disability or death—is directly linked to the drug's mechanism and risk factors. Legal claims often focus on whether warnings were adequate and whether the patient was properly monitored. The timeline between starting Tysabri and PML diagnosis is critical; longer treatment duration, especially beyond two years, increases risk. Patients with anti-JCV antibodies and prior immunosuppressant use are at highest risk. Settlement amounts may reflect medical costs, loss of income, and pain and suffering, but each case depends on individual circumstances and jurisdiction. In summary, Tysabri-associated PML is a serious adverse event with a clear pharmacological basis. The FDA-mandated warnings and monitoring programs aim to mitigate risk, but they cannot prevent all cases. Patients and healthcare providers must remain vigilant for early symptoms, and those affected may seek legal recourse based on inadequate warnings or failure to monitor. Evidence from clinical trials and postmarketing data underscores the need for careful risk-benefit assessment when using Tysabri.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Tysabri and Progressive Multifocal Leukoencephalopathy?

Tysabri (natalizumab) is a biologic therapy that increases the risk of PML, a severe brain infection caused by the JC virus. The drug works by blocking lymphocyte migration into the brain, which reduces immune surveillance and allows the virus to reactivate. The FDA has issued a boxed warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the main risk factors for developing PML while on Tysabri?

Three key risk factors have been identified: presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients with all three factors are at highest risk.

Can I file a lawsuit if I developed PML after taking Tysabri?

Yes, patients who developed PML after Tysabri exposure may have legal claims based on inadequate warnings or failure to monitor. Settlement amounts vary depending on individual circumstances, including medical costs, lost income, and pain and suffering. It is advisable to consult with an experienced injury lawyer.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Tysabri Labeling

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.